As of 2026-04-09, the Relative Valuation of Alnylam Pharmaceuticals Inc (ALNY) is 44.50 USD. This relative valuation is based on P/E multiples. With the latest stock price at 327.25 USD, the upside of Alnylam Pharmaceuticals Inc based on Relative Valuation is -86.4%.
The range of the Relative Valuation is 31.32 - 94.27 USD.
| Range | Selected | |
| Trailing P/E multiples | 13.2x - 17.4x | 14.8x |
| Forward P/E multiples | 18.7x - 33.7x | 19.3x |
| Fair Price | 31.32 - 94.27 | 44.50 |
| Upside | -90.4% - -71.2% | -86.4% |
| Date | P/E |
| 2026-04-07 | 133.53 |
| 2026-04-06 | 139.63 |
| 2026-04-02 | 134.78 |
| 2026-04-01 | 138.95 |
| 2026-03-31 | 139.86 |
| 2026-03-30 | 133.61 |
| 2026-03-27 | 134.15 |
| 2026-03-26 | 138.71 |
| 2026-03-25 | 138.94 |
| 2026-03-24 | 130.21 |
| 2026-03-23 | 129.62 |
| 2026-03-20 | 131.95 |
| 2026-03-19 | 131.50 |
| 2026-03-18 | 133.07 |
| 2026-03-17 | 135.44 |
| 2026-03-16 | 134.80 |
| 2026-03-13 | 132.48 |
| 2026-03-12 | 134.09 |
| 2026-03-11 | 135.44 |
| 2026-03-10 | 136.27 |
| 2026-03-09 | 136.78 |
| 2026-03-06 | 135.54 |
| 2026-03-05 | 135.48 |
| 2026-03-04 | 138.35 |
| 2026-03-03 | 134.69 |
| 2026-03-02 | 137.41 |
| 2026-02-27 | 140.72 |
| 2026-02-26 | 140.01 |
| 2026-02-25 | 138.37 |
| 2026-02-24 | 140.69 |
| 2026-02-23 | 139.22 |
| 2026-02-20 | 142.11 |
| 2026-02-19 | 143.45 |
| 2026-02-18 | 140.62 |
| 2026-02-17 | 140.59 |
| 2026-02-13 | 132.90 |
| 2026-02-12 | 130.39 |
| 2026-02-11 | 136.23 |
| 2026-02-10 | 136.52 |
| 2026-02-09 | 135.26 |
| 2026-02-06 | 138.71 |
| 2026-02-05 | 140.01 |
| 2026-02-04 | 148.77 |
| 2026-02-03 | 148.70 |
| 2026-02-02 | 143.34 |
| 2026-01-30 | 142.90 |
| 2026-01-29 | 146.59 |
| 2026-01-28 | 147.77 |
| 2026-01-27 | 149.95 |
| 2026-01-26 | 152.74 |